Author

Jeffrey Narayan

Institutions: University of Alberta, Royal Alexandra Hospital

Observed institutions: University of Alberta, Royal Alexandra Hospital

ORCID: 0000-0001-6046-5430

Observed ORCID: 0000-0001-6046-5430

OpenAlex ID: A5056201608

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

2021 · Philippe Bégin, Jeannie Callum, et al. · Nature Medicine · 265

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

2020 · Renato Mantegazza, Gil I. Wolfe, et al. · Neurology · 87

Eculizumab improves fatigue in refractory generalized myasthenia gravis

2019 · Henning Andersen, Renato Mantegazza, et al. · Quality of Life Research · 61

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

2019 · Hiroyuki Murai, Akiyuki Uzawa, et al. · Journal of the Neurological Sciences · 24

Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

2022 · Philippe Bégin, Jeannie Callum, et al. · Nature Medicine · 4

Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19

2022 · Philippe Bégin, Jeannie Callum, et al. · Nature Medicine · 1

Works count: 6

Citation count: 442

H-index: 4

I10-index: 4